Table 3.

Subgroup Analyses of Adjusted Associations Between Physician Tumor Board Participation Patterns and All-Cause Patient Mortality^*

Cancer Type	All Respondents					Tumor Board Participants Only
	Attends Tumor Board Weekly (v < weekly or never)					Serves Treatment Planning Function					Includes Evaluation of Treatment Decisions					Reviews Only Challenging Patient Cases					Reviews Variety of Cancer Sites					Serves As Teaching Session (no patient case review)
	No. of Patients	No. of Physicians	HR	95% CI	P	No. of Patients	No. of Physicians	HR	95% CI	P	No. of Patients	No. of Physicians	HR	95% CI	P	No. of Patients	No. of Physicians	HR	95% CI	P	No. of Patients	No. of Physicians	HR	95% CI	P	No. of Patients	No. of Physicians	HR	95% CI	P
NSCLC, stage
I	503	226	0.8	0.6 to 1.0	.058	435	201	0.9	0.6 to 1.4	.75	427	200	0.7	0.5 to 1.2	.20	435	201	1.1	0.8 to 1.5	.44	424	199	1.4	1.0 to 1.9	.06	427	199	1.1	0.6 to 2.2	.71
II	187	131	1.0	0.5 to 1.7	.86	162	117	1.8	0.9 to 3.7	.12	158	115	2.3	0.5 to 10.0	.26	162	117	0.9	0.5 to 1.7	.75	160	116	0.8	0.4 to 1.7	.54	159	115	0.7	0.3 to 1.8	.52
III	555	289	0.9	0.7 to 1.1	.42	516	266	0.9	0.7 to 1.1	.32	509	264	1.4	1.0 to 2.1	.08	514	264	0.9	0.7 to 1.1	.38	514	264	0.9	0.7 to 1.2	.47	510	262	0.9	0.7 to 1.2	.63
IV	632	314	1.0	0.9 to 1.3	.69	599	292	1.0	0.8 to 1.3	.82	587	290	1.1	0.8 to 1.4	.64	595	289	0.8	0.7 to 1.0	.03	598	292	1.2	1.0 to 1.6	.09	585	289	0.9	0.6 to 1.2	.37
SCLC
Limited	105	85	1.4	0.8 to 2.7	.26	98	80	1.5	0.7 to 3.4	.33	94	79	0.4	0.1 to 1.8	.24	97	79	1.8	1.0 to 3.3	.06	98	80	4.1	1.0 to 17.2	.06	93	78	3.0	1.1 to 8.6	.04
Extensive	116	91	0.6	0.3 to 1.0	.04	115	90	0.8	0.4 to 1.6	.50	113	89	1.8	0.8 to 4.2	.19	113	88	0.6	0.3 to 1.0	.04	115	90	1.1	0.3 to 4.0	.84	110	86	3.9	1.8 to 8.3	< .001
CRC, stage
I	517	318	0.8	0.5 to 1.2	.22	477	289	1.1	0.6 to 1.8	.85	476	289	1.1	0.5 to 2.2	.89	480	290	0.8	0.5 to 1.2	.35	464	286	2.4	0.7 to 8.6	.16	476	290	0.9	0.4 to 1.8	.74
II	696	426	0.9	0.6 to 1.2	.38	636	386	0.9	0.6 to 1.4	.73	636	386	0.7	0.4 to 1.4	.33	633	386	1.2	0.9 to 1.7	.15	630	385	1.8	0.8 to 4.0	.13	633	386	1.3	0.8 to 2.0	.32
III	829	485	1.1	0.9 to 1.5	.32	769	446	1.0	0.7 to 1.3	.87	766	446	1.5	0.9 to 2.4	.10	773	447	0.9	0.7 to 1.1	.33	766	445	0.9	0.5 to 1.5	.56	764	442	0.8	0.5 to 1.2	.30
IV	415	300	0.7	0.6 to 0.9	.007	395	284	0.9	0.7 to 1.2	.48	390	283	1.2	0.8 to 1.6	.42	389	282	1.0	0.8 to 1.3	.94	391	281	1.3	0.8 to 2.1	.31	386	282	0.8	0.6 to 1.2	.30

NOTE. Bold font indicates significance.

Abbreviations: CRC, colorectal cancer; HR, hazard ratio for mortality; NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer.

^*Unit of analysis is patient-specified link to surgeon, medical oncologist, or radiation oncologist. Each set of columns represents a set of models including one tumor board feature, and each row represents model results for specific stage and disease type. Models adjusted for physician age, sex, specialty, practice structure, teaching status, No. of patients seen per month with linked patient's cancer type, and National Cancer Institute cancer center affiliation. Also adjusted for patient age, sex, race, marital status, educational attainment, income, and No. of comorbid conditions. Models for CRC also adjusted for disease site (colon, rectal, or other [eg, both colon and rectal]). For ≤ 25 patients per model, multiple imputation was not performed for some items because of partially completed survey versions; these patients were excluded from multivariable analyses.